8-K: Propanc Biopharma Secures $27,500 Convertible Note for Working Capital

Propanc Biopharma has entered into a securities purchase agreement, securing a $27,500 convertible note to bolster its working capital.

Summary

• Propanc Biopharma has obtained a $27,500 convertible note from GS Capital Partners, with a purchase price of $25,000 due to an original issue discount of $2,500.
• The note bears an 8% annual interest rate, with a maturity date of October 12, 2024.
• Interest payments can be made in common stock, and the note can be converted into common stock at a fixed price of $0.0017 per share, or $0.001 per share if the stock trades below $0.0014 for more than five consecutive days.
• In the event of default, the conversion price will be the lowest trading price of the common stock for the ten days prior to the default.
• The company has the option to prepay the note with premiums ranging from 110% to 125% of the principal plus accrued interest, depending on the prepayment date within the first 180 days.
• The note includes provisions for redemption at 150% of the principal plus accrued interest in the event of a sale of the company or a merger, or the holder can elect to convert the note into common stock prior to such event.
• The company has reserved 64,000,000 shares of common stock for potential conversions under this note.

Sentiment

Score: 4

Explanation: The document indicates a necessary but potentially risky financing move. While the capital injection is positive, the terms of the convertible note, including the potential for significant dilution and high default interest, raise concerns.

Positives

• The convertible note provides Propanc Biopharma with $25,000 in immediate working capital.
• The conversion feature allows the investor to participate in potential upside of the company's stock.
• The prepayment options provide flexibility for the company to manage its debt.
• The company has reserved a significant number of shares for potential conversion, indicating a commitment to fulfilling its obligations.

Negatives

• The note carries an 8% interest rate, which increases to 24% in the event of default, potentially increasing the company's financial burden.
• The conversion price can be adjusted downwards if the stock price declines, potentially leading to significant dilution for existing shareholders.
• The company is subject to various events of default, which could trigger immediate repayment of the note.
• The company has to pay a premium if they want to prepay the note within the first 180 days.

Risks

• The company's stock price could fall below $0.0014 per share, triggering a lower conversion price and increased dilution.
• The company could default on the note, leading to a 24% interest rate and potential legal action.
• The company may face challenges in maintaining its listing on the OTC markets, which is an event of default.
• The company's ability to raise additional capital may be impacted by the terms of this note.

Future Outlook

The company intends to use the net proceeds from the note for general working capital purposes.

Industry Context

This type of financing is common for small, publicly traded companies seeking to raise capital, particularly those in the biotechnology sector. The terms of the note, including the conversion price and default provisions, are typical for this type of agreement.

Comparison to Industry Standards

• Convertible notes are a common financing tool for small-cap biotech companies like Propanc Biopharma.
• The 8% interest rate is within the typical range for such notes, although the 24% default rate is high.
• The conversion price of $0.0017 per share, with a potential decrease to $0.001, is reflective of the company's current stock price and risk profile.
• The prepayment premiums are also standard in these types of agreements, designed to compensate the investor for early repayment.
• Similar companies often use convertible notes to bridge funding gaps while pursuing research and development milestones.

Stakeholder Impact

• Shareholders may experience dilution if the note is converted into common stock.
• Creditors may be impacted by the terms of the note, particularly in the event of default.
• Employees may be affected by the company's financial stability and ability to operate.
• Customers and suppliers may be indirectly impacted by the company's financial health.

Next Steps

• The company will use the funds for general working capital purposes.
• The company needs to monitor its stock price to avoid triggering a lower conversion price.
• The company must ensure compliance with all terms of the note to avoid default.
• The company needs to maintain its listing on the OTC markets.

Key Dates

Keywords

convertible note, working capital, securities purchase agreement, common stock, conversion price, interest rate, default, prepayment, dilution, OTC markets